jurnalul român de psihofarmacologie romanian journal of ...
jurnalul român de psihofarmacologie romanian journal of ... jurnalul român de psihofarmacologie romanian journal of ...
Bibliografie 1. Krause J.E., Chirgwin J.M., Carter M.S., Xu Z.S., Hershey A.D., 1987 – Three rat preprotachykinin mRNAs encode the neuropeptides substance P and neurokinin A. Proc. Natl. Acad. Sci. USA, 84, 881-885. 2. Fiskerstrand C., Quinn J.P., 1996 – The molecular biology of preprotachykinin-A gene expression. Neuropeptides, 30, 602-610. 3. Hokfelt T., Pernow B., Wahren J., 2001 – Substance P: a pioneer amongst neuropeptides. J. Intern. Med., 249, 27-40. 4. Wang L.H., Ahmad S., Benter I.F., Chow A., Mizutani S., Ward P.E., 1991 – Differential processing of substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV, aminopeptidase M and angiotensin cinverting enzyme. Peptides, 12, 1357-1364. 5. Csuhai E., Little S.S., Hersh L.B., 1995 – Inactivation of neuropeptides. Prog. Brain Res., 104, 131-142. 6. Stahl S.M., 1999 – Peptides and psychiatry. Part I. How synthesis of neuropeptides differs from classical neurotransmitter synthesis. J. Clin. Psychiatry, 60, 5-6. 7. Li Y.Q., Wang Z.M., Zheng H.X., Shi J.W., 1996 – Central origins of substance P-like immunoreactive fibers and terminals in the spinal trigeminal caudal subnucleus in the rat. Brain Res., 719, 219-224. 8. Chawla M.K., Gutierrez G.M., Young W.S. III, McMullen N.T., Rance N.E., 1997 – Localization of neurons exprssing substance P and neurokinin B gene transcripts in the human hypothalamus and basal forebrain. J. Comp. Neurol., 384, 429-442. 9. Hokfelt T., Reid M., Herrera-Marschitz M., et. al., 1991 – Tachykinins and related peptides in the substantia nigra and neostriatum. Ann. NY Acad. Sci., 632, 192-197. 10. Lucas L.R., Harlan R.E., 1995 – Cholinergic regulation of tachykinin- and enkephalin- gene expression in the rat striatum. Brain Res. Mol. Brain Res., 30, 181-195. 11. Jaber M., Normand E., Bloch B., 1995 – Effect of reserpine treatment on enkephalin mRNA level in the rat striatum: an in situ hybridization study. Brain Res. Mol. Brain Res., 32, 165-160. 12. Sarau H.M., Moneey J.L., Schmidt D.B. et. al., 2000 – Evidence that the proposed novel human „neurokinin-4” receptor is pharmacologically similar to the human neurokinin-3 receptor but is not of human origin. Mol. Pharmacol., 58, 552-559. 13. Gerard N.P., Garraway L.A., Eddy R.L. Jr., et. al., 1991 – Human substance P receptor (NK1): organisation of the gene, chromosome localization, and functional expression of cDNA clones. Biochemistry., 30, 10640-10646. 14. Li I., Kaneko T., Mizuno N., 2001 – Colocalization of neuronal nitric oxide synthase and neurokinin-1 receptor in striatal interneurons in the rat. Neuroscience Lett., 310, 109-112. 78
15. Saria A., 1999 – The tachykinin NK1 receptor in the brain : pharmacology and putative functions. Eur. J. Pharmacol., 375, 51-60. 16. Ribeiro S.J., Teixeira R.M., Calixto J.B., De Lima T.C., 1999 – Tachykinin NK3 receptor involvement in anxiety. Neuropeptides, 33, 181-188. 17. 17.Schwartz M.J., Chiang S., Müller N., Ackenhal M., 2001 – T-helper-1 and T-helper-2 reponses in psychiatric disorders. Brain. Behav. Immun., 15, 340-370. 18. Snider R.M., Constantine J.W., Lowe J.A. III, et. al., 1991 – A potent nonpeptide antagonist of the substance P (NK1) receptor. Science, 251, 435-437. 19. Rupniak N.M.J., Kramer M.S., 1999 – Discovery of the antidepressant anti-emetic efficacy of substance P antagonists. Trends Pharmacol. Sci., 20, 485-490. 20. Panocka I., Massi M., Lapo I., Swiderski T., Kowalczyk M., Sadowski B., 2001 – Antidepressant type effect on the NK3 tachykinin receptor agonist – aminosenktide – in mouse lines differing in endogenous opioid system activity. Peptides, 22, 1037-1042. 21. Ribeiro S.J., De Lima T.C., 1998 – Naloxone – induced changes in tachykinin NK3 receptor modulation of experimental anxiety in mice. Neurosc. Lett., 258, 155-158. 22. Humpel S., Saria A., 1993 – Characterisation of neurokinin binding sites in rat brain membranes using highly selective ligands. Neuropeptides, 25, 65-71. 23. Shpeard S.L., Williamson D.J., Williams J. et. al., 1995 – Comparison of the effects of sumatriptan and the NK1 antagonist CP= 99,994 on plasma extravasation in dura mater and cfos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology, 34, 255-261. 24. Watson J.W., Gonsalves S.F., Fossa A.A. et. al., 1995 – The anti-emetic effects of CP- 99,994 in the ferret and the dog: role of the NK1 receptor. Br. J. Pharmacol., 115, 84-94. 25. Elliott P.J., Nemeroff C.B., Kilts C. D., 1986 – Evidence for a tonic facilitatory influence of substance P on dopamine release in the nucleus accumbens. Brain Res., 385,379-382. 26. Marco N., Thirion A., Mons G. et. al., 1998 – Activation of dopaminergic and cholinergic neurotransmission by tachykinin NK3 receptor stimulation: an in vivo microdialysis approach in guinea pig. Neuropeptides, 32, 481-488. 27. Mantyh P.W., Hunt S.P., Maggio J.E., 1984 – Substance P receptors: localization by light microscopic autoradiography in rat brain using [H3] SP as the radioligand. Brain Res., 307, 147-165. 28. Kramer M.S., Cutler W., Feighner J. et. al., 1998 – Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science, 281, 1640-1645. 29. Kramer M.S., Ball W.A., Reines S.A., 2001 – Replication of the efficacy and tolerability of substance P antagonists in patients with major depression. American College of Neuropsychopharmacology (ACNP) 40-th Anniversary Scientific Abstract Book, Abstract 128. 79
- Page 31 and 32: c) Studiul Zürich (Jules Angst, 19
- Page 33 and 34: mai cu seamă a terapiilor combinat
- Page 35 and 36: Descoperirea în ordine cronologic
- Page 37 and 38: Succesiunea de etape istorico-crono
- Page 39 and 40: prurigo, etc) interpretate diagnost
- Page 41 and 42: Antidepresivele de generaţia a pat
- Page 43 and 44: Bibliografie 1. Frank E, Prien RF,
- Page 45 and 46: TERAPIA BIOLOGICĂ A DEPRESIILOR I.
- Page 47 and 48: Indicaţia primară a Carbamazepine
- Page 49 and 50: 3. Currier, B. M., Murray, G. & Wel
- Page 51 and 52: În cursul tratamentului pot interv
- Page 53 and 54: Aplicând scala MADRS la pacienţii
- Page 55 and 56: Proprietăţile antihistaminice H1
- Page 57 and 58: Utilizarea antihistaminicelor H1 ne
- Page 59 and 60: s-a dovedit într-un studiu multice
- Page 61 and 62: În plus, depresia este corelată c
- Page 63 and 64: 21. Juhlin, L., 1981 - Recurrent ur
- Page 65 and 66: DEPRESIA ŞI EPILEPSIA G. Bădescu,
- Page 67 and 68: Rolul GABA în depresie - un defici
- Page 69 and 70: menţionează 25 % simptome psihiat
- Page 71 and 72: 10. Kanner, A.M., Palac, S., 2000 -
- Page 73 and 74: De la descoperirea primului antidep
- Page 75 and 76: Tratamentul de lungă durată cu am
- Page 77 and 78: Tachikininele produc fenomenul de
- Page 79 and 80: Hiperactivitatea locomotorie şi mo
- Page 81: Efectele secundare în sfera sexual
- Page 85 and 86: Termenul de neuropsihoendocrinologi
- Page 87 and 88: Atât pacienţii depresivi cât şi
- Page 89 and 90: Bibliografie selectivă 1. Agid, O.
- Page 91 and 92: TRATAMENTUL CU SERTRALINĂ ÎN TULB
- Page 93 and 94: În cel de-al doilea lot, a existat
- Page 95 and 96: EFECTUL SEDATIV ŞI ALTERAREA PERFO
- Page 97 and 98: La doze terapeutice, clorfeniramina
- Page 99 and 100: arierei hematoencefalice de către
- Page 101 and 102: decât pentru loratadină, fără d
- Page 103 and 104: viteză de 95 km/h, reprezintă o c
- Page 105 and 106: 6. Hindmarch, I., Shamsi, Z., 1999
- Page 107 and 108: 35. Tashiro, M., Mochizuki, H., Iwa
- Page 109 and 110: În insuficienţa hepatică cronic
- Page 111 and 112: În hiperamoniemia moderată cronic
- Page 113 and 114: c. GABA (acid gamma aminobutiric) e
- Page 115 and 116: Iată deci cum factori diferiţi, c
- Page 117 and 118: Perspectiva psihosocială Buss - 19
- Page 119 and 120: În sindromul Kluver-Bucy (ablaţia
- Page 121 and 122: Bibliografie selectivă 1. Allen, T
- Page 123 and 124: International Journal for Postgradu
- Page 125 and 126: familia pacientului, formularea pla
- Page 127 and 128: Participarea familiei trebuie să i
- Page 129 and 130: VI. Antipsihoticele convenţionale:
- Page 131 and 132: Chiar dacă toate aceste medicament
Bibliografie<br />
1. Krause J.E., Chirgwin J.M., Carter M.S., Xu Z.S., Hershey A.D., 1987 – Three rat<br />
preprotachykinin mRNAs enco<strong>de</strong> the neuropepti<strong>de</strong>s substance P and neurokinin A. Proc.<br />
Natl. Acad. Sci. USA, 84, 881-885.<br />
2. Fiskerstrand C., Quinn J.P., 1996 – The molecular biology <strong>of</strong> preprotachykinin-A gene<br />
expression. Neuropepti<strong>de</strong>s, 30, 602-610.<br />
3. Hokfelt T., Pernow B., Wahren J., 2001 – Substance P: a pioneer amongst neuropepti<strong>de</strong>s. J.<br />
Intern. Med., 249, 27-40.<br />
4. Wang L.H., Ahmad S., Benter I.F., Chow A., Mizutani S., Ward P.E., 1991 – Differential<br />
processing <strong>of</strong> substance P and neurokinin A by plasma dipeptidyl(amino)peptidase IV,<br />
aminopeptidase M and angiotensin cinverting enzyme. Pepti<strong>de</strong>s, 12, 1357-1364.<br />
5. Csuhai E., Little S.S., Hersh L.B., 1995 – Inactivation <strong>of</strong> neuropepti<strong>de</strong>s. Prog. Brain Res.,<br />
104, 131-142.<br />
6. Stahl S.M., 1999 – Pepti<strong>de</strong>s and psychiatry. Part I. How synthesis <strong>of</strong> neuropepti<strong>de</strong>s differs<br />
from classical neurotransmitter synthesis. J. Clin. Psychiatry, 60, 5-6.<br />
7. Li Y.Q., Wang Z.M., Zheng H.X., Shi J.W., 1996 – Central origins <strong>of</strong> substance P-like<br />
immunoreactive fibers and terminals in the spinal trigeminal caudal subnucleus in the rat.<br />
Brain Res., 719, 219-224.<br />
8. Chawla M.K., Gutierrez G.M., Young W.S. III, McMullen N.T., Rance N.E., 1997 –<br />
Localization <strong>of</strong> neurons exprssing substance P and neurokinin B gene transcripts in the<br />
human hypothalamus and basal forebrain. J. Comp. Neurol., 384, 429-442.<br />
9. Hokfelt T., Reid M., Herrera-Marschitz M., et. al., 1991 – Tachykinins and related pepti<strong>de</strong>s<br />
in the substantia nigra and neostriatum. Ann. NY Acad. Sci., 632, 192-197.<br />
10. Lucas L.R., Harlan R.E., 1995 – Cholinergic regulation <strong>of</strong> tachykinin- and enkephalin- gene<br />
expression in the rat striatum. Brain Res. Mol. Brain Res., 30, 181-195.<br />
11. Jaber M., Normand E., Bloch B., 1995 – Effect <strong>of</strong> reserpine treatment on enkephalin mRNA<br />
level in the rat striatum: an in situ hybridization study. Brain Res. Mol. Brain Res., 32, 165-160.<br />
12. Sarau H.M., Moneey J.L., Schmidt D.B. et. al., 2000 – Evi<strong>de</strong>nce that the proposed novel<br />
human „neurokinin-4” receptor is pharmacologically similar to the human neurokinin-3<br />
receptor but is not <strong>of</strong> human origin. Mol. Pharmacol., 58, 552-559.<br />
13. Gerard N.P., Garraway L.A., Eddy R.L. Jr., et. al., 1991 – Human substance P receptor<br />
(NK1): organisation <strong>of</strong> the gene, chromosome localization, and functional expression <strong>of</strong><br />
cDNA clones. Biochemistry., 30, 10640-10646.<br />
14. Li I., Kaneko T., Mizuno N., 2001 – Colocalization <strong>of</strong> neuronal nitric oxi<strong>de</strong> synthase and<br />
neurokinin-1 receptor in striatal interneurons in the rat. Neuroscience Lett., 310, 109-112.<br />
78
Change language